Articles with public access mandates - Elie TraerLearn more
Not available anywhere: 2
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia
JT Leonard, JSJ Rowley, CA Eide, E Traer, B Hayes-Lattin, M Loriaux, ...
Science translational medicine 8 (354), 354ra114-354ra114, 2016
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, V …
CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation
MJ Gordon, P Tardi, MM Loriaux, SE Spurgeon, E Traer, T Kovacsovics, ...
Leukemia Research 53, 39-49, 2017
Mandates: US National Institutes of Health, V Foundation, USA
Available somewhere: 33
Functional genomic landscape of acute myeloid leukaemia
JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ...
Nature 562 (7728), 526-531, 2018
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, V …
Proteogenomic and metabolomic characterization of human glioblastoma
LB Wang, A Karpova, MA Gritsenko, JE Kyle, S Cao, Y Li, D Rykunov, ...
Cancer cell 39 (4), 509-528. e20, 2021
Mandates: US Department of Energy, US National Institutes of Health
Proteogenomic characterization of endometrial carcinoma
Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ...
Cell 180 (4), 729-748. e26, 2020
Mandates: US Department of Energy, US National Institutes of Health
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma
C Huang, L Chen, SR Savage, RV Eguez, Y Dou, Y Li, ...
Cancer cell 39 (3), 361-379. e16, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia
A Carey, DK Edwards, CA Eide, L Newell, E Traer, BC Medeiros, ...
Cell reports 18 (13), 3204-3218, 2017
Mandates: US National Science Foundation, US National Institutes of Health, Howard …
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ...
Cancer cell 40 (8), 850-864. e9, 2022
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, V …
FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia
E Traer, J Martinez, N Javidi-Sharifi, A Agarwal, J Dunlap, I English, ...
Cancer research 76 (22), 6471-6482, 2016
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, ...
Nature medicine 26 (12), 1852-1858, 2020
Mandates: US National Institutes of Health
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
E Traer, R MacKenzie, J Snead, A Agarwal, AM Eiring, T O'Hare, ...
Leukemia 26 (5), 1140-1143, 2012
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, National …
Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance
N Javidi-Sharifi, E Traer, J Martinez, A Gupta, T Taguchi, J Dunlap, ...
Cancer research 75 (5), 880-891, 2015
Mandates: US National Institutes of Health, V Foundation, USA
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid-and lymphoid-derived hematologic malignancies
SE Kurtz, CA Eide, A Kaempf, V Khanna, SL Savage, A Rofelty, I English, ...
Proceedings of the National Academy of Sciences 114 (36), E7554-E7563, 2017
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, V …
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
SK Joshi, T Nechiporuk, D Bottomly, PD Piehowski, JA Reisz, ...
Cancer cell 39 (7), 999-1014. e8, 2021
Mandates: US Department of Energy, US National Institutes of Health, Howard Hughes …
Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance
S Viola, E Traer, J Huan, NI Hornick, JW Tyner, A Agarwal, M Loriaux, ...
British journal of haematology 172 (6), 983, 2015
Mandates: US National Institutes of Health
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells
N Javidi-Sharifi, J Martinez, I English, SK Joshi, R Scopim-Ribeiro, ...
elife 8, e40033, 2019
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
G Garcia-Manero, Y Abaza, K Takahashi, BC Medeiros, M Arellano, ...
Blood advances 3 (4), 508-518, 2019
Mandates: US National Institutes of Health
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
E Traer, N Javidi-Sharifi, A Agarwal, J Dunlap, I English, J Martinez, ...
Blood, The Journal of the American Society of Hematology 123 (10), 1516-1524, 2014
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
CA Lachowiez, N Long, J Saultz, A Gandhi, LF Newell, B Hayes-Lattin, ...
Blood Advances 7 (9), 1899-1909, 2023
Mandates: US National Institutes of Health
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
S Bandyopadhyay, J Li, E Traer, JW Tyner, A Zhou, ST Oh, JX Cheng
PLoS One 12 (7), e0179558, 2017
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program